{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T06:38:25Z","timestamp":1772779105575,"version":"3.50.1"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr HIV\/AIDS Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11904-025-00762-z","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:52:01Z","timestamp":1762509121000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Growing Up with HIV: A Comprehensive Review of Treatment and Care in Low- and Middle-Income Countries"],"prefix":"10.1007","volume":"22","author":[{"given":"Brigid E.","family":"O\u2019Brien","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Maidl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob L.","family":"Todd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Abadie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moses","family":"Mugerwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine R.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Perry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"762_CR1","unstructured":"WHO. HIV statistics, globally and by WHO region, 2024.\u00a02024."},{"key":"762_CR2","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jac\/dkw463","volume":"72","author":"RS Boerma","year":"2017","unstructured":"Boerma RS, Sigaloff KCE, Akanmu AS, et al. Alarming increase in pretreatment HIV drug resistance in children living in sub-Saharan africa: A systematic review and meta-analysis. J Antimicrob Chemother. 2017;72:365\u201371. https:\/\/doi.org\/10.1093\/jac\/dkw463.","journal-title":"J Antimicrob Chemother"},{"key":"762_CR3","unstructured":"UNAIDS. Ending the AIDS epidemic for adolescents, with adolescents.\u00a02016."},{"key":"762_CR4","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1097\/INF.0b013e3182044930","volume":"30","author":"P Nahirya-Ntege","year":"2011","unstructured":"Nahirya-Ntege P, Musiime V, Naidoo B, et al. Low incidence of abacavir hypersensitivity reaction among African children initiating antiretroviral therapy. Pediatr Infect Dis J. 2011;30:535\u20137. https:\/\/doi.org\/10.1097\/INF.0b013e3182044930.","journal-title":"Pediatr Infect Dis J"},{"key":"762_CR5","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1016\/S0140-6736(12)62198-9","volume":"381","author":"DM Gibb","year":"2013","unstructured":"Gibb DM. Routine versus clinically driven laboratory monitoring and Fi rst-line antiretroviral therapy strategies in African children with HIV (ARROW): A 5-year open-label randomised factorial trial. Lancet. 2013;381:1391\u2013403. https:\/\/doi.org\/10.1016\/S0140-6736(12)62198-9.","journal-title":"Lancet"},{"key":"762_CR6","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S1473-3099(15)00319-9","volume":"16","author":"V Mulenga","year":"2016","unstructured":"Mulenga V, Musiime V, Kekitiinwa A, et al. Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial. Lancet Infect Dis. 2016;16:169. https:\/\/doi.org\/10.1016\/S1473-3099(15)00319-9.","journal-title":"Lancet Infect Dis"},{"key":"762_CR7","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1056\/nejmoa2404597","volume":"392","author":"V Musiime","year":"2025","unstructured":"Musiime V, Bwakura-Dangarembizi M, Szubert AJ, et al. Second-line antiretroviral therapy for children living with HIV in Africa. N Engl J Med. 2025;392:1917\u201332. https:\/\/doi.org\/10.1056\/nejmoa2404597.","journal-title":"N Engl J Med"},{"key":"762_CR8","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1056\/nejmoa0800971","volume":"359","author":"A Violari","year":"2008","unstructured":"Violari A, Cotton MF, Gibb DM, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 2008;359:2233\u201344. https:\/\/doi.org\/10.1056\/nejmoa0800971.","journal-title":"N Engl J Med"},{"key":"762_CR9","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2108793","author":"A Turkova","year":"2021","unstructured":"Turkova A, White E, Mujuru HA, et al. Dolutegravir as first- or second-line treatment for HIV-1 infection in children. N Engl J Med. 2021. https:\/\/doi.org\/10.1056\/nejmoa2108793.","journal-title":"N Engl J Med"},{"key":"762_CR10","doi-asserted-by":"publisher","first-page":"e381","DOI":"10.1016\/S2352-3018(22)00092-3","volume":"9","author":"NI Paton","year":"2022","unstructured":"Paton NI, Musaazi J, Kityo C, et al. Efficacy and safety of dolutegravir or Darunavir in combination with lamivudine plus either Zidovudine or Tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised,\u00a0non-inferiority trial. Lancet HIV. 2022;9:e381\u201393. https:\/\/doi.org\/10.1016\/S2352-3018(22)00092-3.","journal-title":"Lancet HIV"},{"key":"762_CR11","doi-asserted-by":"publisher","DOI":"10.1093\/JPIDS\/PIY139","author":"RM Viani","year":"2020","unstructured":"Viani RM, Ruel T, Alvero C, et al. Long-term safety and efficacy of dolutegravir in treatment-experienced adolescents with human immunodeficiency virus infection: results of the Impaact P1093 study. J Pediatr Infect Dis Soc. 2020. https:\/\/doi.org\/10.1093\/JPIDS\/PIY139.","journal-title":"J Pediatr Infect Dis Soc"},{"key":"762_CR12","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.3954096","author":"TD Ruel","year":"2021","unstructured":"Ruel TD, Acosta EP, Liu JP, et al. Pharmacokinetics, Safety, tolerability and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1: results of the IMPAACT P1093 Study, a phase I\/II Open-Label trial. SSRN Electron J. 2021. https:\/\/doi.org\/10.2139\/ssrn.3954096.","journal-title":"SSRN Electron J"},{"key":"762_CR13","doi-asserted-by":"publisher","first-page":"26414","DOI":"10.1002\/jia2.26414\/full","volume":"28","author":"E Natukunda","year":"2025","unstructured":"Natukunda E, Gaur AH, Hellstr\u00f6m E, et al. Pharmacokinetics, safety and efficacy of elvitegravir\/cobicistat\/ emtricitabine\/tenofovir Alafenamide in children with HIV aged from 2 years and weighing at least 14 kg. J Int AIDS Soc. 2025;28:26414. https:\/\/doi.org\/10.1002\/jia2.26414\/full.","journal-title":"J Int AIDS Soc"},{"key":"762_CR14","unstructured":"WHO. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV. WHO Guidel 1\u201382.\u00a02018."},{"key":"762_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-022-00608-1","author":"AV Zhao","year":"2022","unstructured":"Zhao AV, Crutchley RD, Guduru RC, et al. A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection. Retrovirology. 2022;19:22. https:\/\/doi.org\/10.1186\/s12977-022-00608-1.","journal-title":"Retrovirology"},{"key":"762_CR16","unstructured":"WHO. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring. recommendations for a public health approach; 2021."},{"key":"762_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009012.pub3","author":"I Eshun-Wilson","year":"2018","unstructured":"Eshun-Wilson I, Okwen MP, Richardson M, Bicanic T. Early versus delayed antiretroviral treatment in HIV-positive people with cryptococcal meningitis. Cochrane Database Syst Rev. 2018;7(7):CD009012.\u00a0https:\/\/doi.org\/10.1002\/14651858.CD009012.pub3.","journal-title":"Cochrane Database Syst Rev"},{"key":"762_CR18","doi-asserted-by":"publisher","unstructured":"T\u00f6r\u00f6k ME, Thi N, Yen B et al. Timing of Initiation of Antiretroviral Therapy in Human Immunodeficiency Virus (HIV)\u2014Associated Tuberculous Meningitis. Clinical Infectious Diseases, 2015;52(11);1374\u20131383. https:\/\/doi.org\/10.1093\/cid\/cir230.","DOI":"10.1093\/cid\/cir230"},{"key":"762_CR19","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1007\/s10461-024-04312-3","volume":"28","author":"L Makonokaya","year":"2024","unstructured":"Makonokaya L, Maida A, Kalitera LU, et al. Early effects of scaling up Dolutegravir-based ARV regimens among children living with HIV in Malawi. AIDS Behav. 2024;28:2148\u201355. https:\/\/doi.org\/10.1007\/s10461-024-04312-3.","journal-title":"AIDS Behav"},{"key":"762_CR20","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1097\/INF.0000000000003878","volume":"42","author":"JM Bacha","year":"2023","unstructured":"Bacha JM, Dlamini S, Anabwani F, et al. Realizing the promise of dolutegravir in effectively treating children and adolescents living with HIV in real-world settings in 6 countries in Eastern and Southern Africa. Pediatr Infect Dis J. 2023;42:576\u201381. https:\/\/doi.org\/10.1097\/INF.0000000000003878.","journal-title":"Pediatr Infect Dis J"},{"key":"762_CR21","unstructured":"Republic of Malawi Ministry of Health. Clinical management of HIV in children and adults.\u00a02022."},{"key":"762_CR22","unstructured":"Republic of Malawi Ministry of Health. National tuberculosis and leprosy guidelines.\u00a02024."},{"key":"762_CR23","unstructured":"WHO. Global tuberculosis report 2023. Geneva. 2023."},{"key":"762_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.5588\/ijtldopen.23.0529","volume":"1","author":"S Verkujl","year":"2024","unstructured":"Verkujl S, Bastard M, Viney K, et al. Global reporting on TB in children and adolescents: how Far have we come and what remains to be done? IJTLD Open. 2024;1:3\u20136. https:\/\/doi.org\/10.5588\/ijtldopen.23.0529.","journal-title":"IJTLD Open"},{"key":"762_CR25","doi-asserted-by":"publisher","unstructured":"Hetherington S, McGuirk S, Powell G, Cutrell A, Naderer O, Spreen B, Lafon S, Pearce G, Steel H. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther. 2001;23(10):1603\u201314. https:\/\/doi.org\/10.1016\/s0149-2918(01)80132-6.","DOI":"10.1016\/s0149-2918(01)80132-6"},{"key":"762_CR26","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/S2352-4642(22)00213-9","volume":"6","author":"J Jesson","year":"2022","unstructured":"Jesson J, Saint-Lary L, Revegue MHDT, et al. Safety and efficacy of abacavir for treating infants, children, and adolescents living with HIV: a systematic review and meta-analysis. Lancet Child Adolesc Health. 2022;6:692\u2013704. https:\/\/doi.org\/10.1016\/S2352-4642(22)00213-9.","journal-title":"Lancet Child Adolesc Health"},{"key":"762_CR27","unstructured":"WHO. Consolidated guidelines on the use of antiretroviral. Drugs for treating and preventing HIV infection; 2016."},{"key":"762_CR28","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1097\/COH.0000000000000248","volume":"11","author":"PM Grant","year":"2016","unstructured":"Grant PM, Cotter AG. Tenofovir and bone health. Curr Opin HIV AIDS. 2016;11:326\u201332.","journal-title":"Curr Opin HIV AIDS"},{"key":"762_CR29","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1080\/17512433.2023.2251387","volume":"16","author":"EC Osuala","year":"2023","unstructured":"Osuala EC, Naidoo A, Dooley KE, et al. Broadening access to Tenofovir alafenamide for the treatment and prevention of HIV-1 infection. Expert Rev Clin Pharmacol. 2023;16:939\u201357. https:\/\/doi.org\/10.1080\/17512433.2023.2251387.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"762_CR30","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad267","author":"H Waalewijn","year":"2023","unstructured":"Waalewijn H, Szubert AJ, Wasmann RE, et al. First pharmacokinetic data of Tenofovir Alafenamide fumarate and Tenofovir with dolutegravir or boosted protease inhibitors in African children: a substudy of the CHAPAS-4 trial. Clin Infect Dis. 2023. https:\/\/doi.org\/10.1093\/cid\/ciad267.","journal-title":"Clin Infect Dis"},{"key":"762_CR31","unstructured":"WHO. 2023 WHO think tank on treatment optimization of HIV: meeting report, Seattle, Washington, United States of America, 23 February 2023.\u00a02023."},{"key":"762_CR32","unstructured":"WHO. Web Annex A. World Health Organization model list of essential medicines.\u00a02023."},{"key":"762_CR33","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/S0140-6736(04)17140-7","volume":"364","author":"ML Newell","year":"2004","unstructured":"Newell ML, Coovadia H, Cortina-Borja M, et al. Mortality of infected and uninfected infants born to HIV-infected mothers in africa: A pooled analysis. Lancet. 2004;364:1236\u201343. https:\/\/doi.org\/10.1016\/S0140-6736(04)17140-7.","journal-title":"Lancet"},{"key":"762_CR34","unstructured":"UNICEF. Understanding and improving viral load suppression in children with HIV in Eastern and Southern Africa; 2021. In: https:\/\/www.unicef.org\/esa\/media\/8206\/file\/VLS-STUDY-2021.pdf."},{"key":"762_CR35","unstructured":"Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Department of Health and Human Services. 2024;I3\u2013I6. Available at: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/pediatric-arv. Accessed 1 November 2025."},{"key":"762_CR36","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1089\/apc.2011.0083","volume":"25","author":"BC Fetzer","year":"2011","unstructured":"Fetzer BC, Mupenda B, Lusiama J, et al. Barriers to and facilitators of adherence to pediatric antiretroviral therapy in a sub-Saharan setting: insights from a qualitative study. AIDS Patient Care STDS. 2011;25:611\u201321. https:\/\/doi.org\/10.1089\/apc.2011.0083.","journal-title":"AIDS Patient Care STDS"},{"key":"762_CR37","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1089\/apc.2007.0110","volume":"22","author":"SL Marhefka","year":"2008","unstructured":"Marhefka SL, Koenig LJ, Allison S, et al. Family experiences with pediatric antiretroviral therapy: responsibilities, barriers, and strategies for remembering medications. AIDS Patient Care STDS. 2008;22:637\u201347. https:\/\/doi.org\/10.1089\/apc.2007.0110.","journal-title":"AIDS Patient Care STDS"},{"key":"762_CR38","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.18.1.20049","author":"OA Adejumo","year":"2015","unstructured":"Adejumo OA, Malee KM, Ryscavage P, et al. Contemporary issues on the epidemiology and antiretroviral adherence of HIV-infected adolescents in sub-Saharan Africa: a narrative review. J Int AIDS Soc. 2015. https:\/\/doi.org\/10.7448\/IAS.18.1.20049.","journal-title":"J Int AIDS Soc"},{"key":"762_CR39","doi-asserted-by":"publisher","first-page":"93","DOI":"10.24875\/AIDSRev.20000101","volume":"22","author":"N Tarantino","year":"2021","unstructured":"Tarantino N, Lowery A, Brown L. Adherence to HIV care and associated health functioning among youth living with HIV in Sub-Saharan Africa. AIDS Rev. 2021;22:93\u2013102. https:\/\/doi.org\/10.24875\/AIDSRev.20000101.","journal-title":"AIDS Rev"},{"key":"762_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0272906","volume":"17","author":"CT Leshargie","year":"2022","unstructured":"Leshargie CT, Demant D, Burrowes S, Frawley J. The proportion of loss to follow-up from antiretroviral therapy (ART) and its association with age among adolescents living with HIV in sub-Saharan africa: A systematic review and meta-analysis. PLoS ONE. 2022;17:1\u201321. https:\/\/doi.org\/10.1371\/journal.pone.0272906.","journal-title":"PLoS ONE"},{"key":"762_CR41","doi-asserted-by":"publisher","unstructured":"Chun HM, Dirlikov E, Hurlston Cox M, et al. Vital Signs: Progress Toward Eliminating HIV as a Global Public Health Threat Through Scale-Up of Antiretroviral Therapy and Health System Strengthening Supported by the U.S. President's Emergency Plan for AIDS Relief - Worldwide, 2004-2022. MMWR Morb Mortal Wkly Rep. 2023;72(12):317-324. https:\/\/doi.org\/10.15585\/mmwr.mm7212e1.","DOI":"10.15585\/mmwr.mm7212e1"},{"key":"762_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2540","author":"IH Mosha","year":"2024","unstructured":"Mosha IH, Nyondo GG, Munishi CG, et al. Prevalence and factors associated with viral non-suppression in people living with HIV receiving antiretroviral therapy in sub-Saharan Africa: a systematic review and meta-analysis. Rev Med Virol. 2024. https:\/\/doi.org\/10.1002\/rmv.2540.","journal-title":"Rev Med Virol"},{"key":"762_CR43","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s11904-021-00568-9","volume":"18","author":"LB Whiteley","year":"2021","unstructured":"Whiteley LB, Olsen EM, Haubrick KK, et al. A review of interventions to enhance HIV medication adherence. Curr HIV AIDS Rep. 2021;18:443\u201357. https:\/\/doi.org\/10.1007\/s11904-021-00568-9.","journal-title":"Curr HIV AIDS Rep"},{"key":"762_CR44","unstructured":"Society for Adolescent Health and Medicine. Improving outcomes for adolescents and young adults living with HIV. Elsevier Inc; 2023."},{"key":"762_CR45","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/COH.0000000000000456","volume":"13","author":"L Hamzah","year":"2018","unstructured":"Hamzah L, Hamlyn E. Sexual and reproductive health in HIV-positive adolescents. Curr Opin HIV AIDS. 2018;13:230\u20135. https:\/\/doi.org\/10.1097\/COH.0000000000000456.","journal-title":"Curr Opin HIV AIDS"},{"key":"762_CR46","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.jadohealth.2017.10.007","volume":"62","author":"T Ramraj","year":"2018","unstructured":"Ramraj T, Jackson D, Dinh T, et al. Adolescent access to care and risk of early mother-to-child HIV transmission. J Adolesc Health. 2018;62:434\u201343. https:\/\/doi.org\/10.1016\/j.jadohealth.2017.10.007.","journal-title":"J Adolesc Health"},{"key":"762_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12981-021-00351-1","volume":"18","author":"G Ayano","year":"2021","unstructured":"Ayano G, Demelash S, Abraha M, Tsegay L. The prevalence of depression among adolescent with HIV\/AIDS: a systematic review and meta-analysis. AIDS Res Ther. 2021;18:1\u201310. https:\/\/doi.org\/10.1186\/s12981-021-00351-1.","journal-title":"AIDS Res Ther"},{"key":"762_CR48","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/bjc.12333","volume":"61","author":"S Shorey","year":"2022","unstructured":"Shorey S, Ng ED, Wong CHJ. Global prevalence of depression and elevated depressive symptoms among adolescents: a systematic review and meta-analysis. Br J Clin Psychol. 2022;61:287\u2013305. https:\/\/doi.org\/10.1111\/bjc.12333.","journal-title":"Br J Clin Psychol"},{"key":"762_CR49","unstructured":"Integration of Mental Health and HIV Interventions, Key Considerations. Geneva: Joint United Nations Programme on HIV\/AIDS and the World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO.\u00a02022."},{"key":"762_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jia2.25741","volume":"24","author":"CA Laurenzi","year":"2021","unstructured":"Laurenzi CA, du Toit S, Ameyan W, et al. Psychosocial interventions for improving engagement in care and health and behavioural outcomes for adolescents and young people living with HIV: a systematic review and meta-analysis. J Int AIDS Soc. 2021;24:1\u201315. https:\/\/doi.org\/10.1002\/jia2.25741.","journal-title":"J Int AIDS Soc"},{"key":"762_CR51","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jadohealth.2022.03.020","volume":"71","author":"CA Laurenzi","year":"2022","unstructured":"Laurenzi CA, Melendez-Torres GJ, Page DT, et al. How do psychosocial interventions for adolescents and young people living with HIV improve adherence and viral load? A realist review. J Adolesc Health. 2022;71:254\u201369. https:\/\/doi.org\/10.1016\/j.jadohealth.2022.03.020.","journal-title":"J Adolesc Health"},{"key":"762_CR52","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.20.4.21528","author":"DL Dahourou","year":"2017","unstructured":"Dahourou DL, Gautier-Lafaye C, Teasdale CA, et al. Transition from paediatric to adult care of adolescents living with HIV in sub-Saharan Africa: Challenges, youth-friendly models, and outcomes. J Int AIDS Soc. 2017. https:\/\/doi.org\/10.7448\/IAS.20.4.21528.","journal-title":"J Int AIDS Soc"},{"key":"762_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4102\/sajhivmed.v26i1.1674","volume":"26","author":"C Petinger","year":"2025","unstructured":"Petinger C, Crowley T, van Wyk B. Transition of adolescents from paediatric to adult HIV care in South africa: A policy review. South Afr J HIV Med. 2025;26:1\u20137. https:\/\/doi.org\/10.4102\/sajhivmed.v26i1.1674.","journal-title":"South Afr J HIV Med"},{"key":"762_CR54","unstructured":"WHO. HIV Drug Resistance Report 2021. Technical report. 2021;\u00a02021."},{"key":"762_CR55","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s40471-021-00268-3","volume":"8","author":"WLA Koay","year":"2021","unstructured":"Koay WLA, Kose-Otieno J, Rakhmanina N. HIV drug resistance in children and adolescents: always a challenge? Curr Epidemiol Rep. 2021;8:97\u2013107. https:\/\/doi.org\/10.1007\/s40471-021-00268-3.","journal-title":"Curr Epidemiol Rep"},{"key":"762_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2989\/16085906.2019.1676802","volume":"19","author":"K Anderson","year":"2020","unstructured":"Anderson K, Muloiwa R, Davies MA. Long-term outcomes in perinatally HIV-infected adolescents and young adults on antiretroviral therapy: a review of South African and global literature. Afr J AIDS Res. 2020;19:1\u201312. https:\/\/doi.org\/10.2989\/16085906.2019.1676802.","journal-title":"Afr J AIDS Res"},{"key":"762_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0300456","volume":"19","author":"EN Takem","year":"2024","unstructured":"Takem EN, Coox C, Shang J, et al. The association between HIV pretreatment drug resistance and virological outcomes in children and adults in sub-Saharan africa: A systematic review and meta-analysis. PLoS ONE. 2024;19:1\u201318. https:\/\/doi.org\/10.1371\/journal.pone.0300456.","journal-title":"PLoS ONE"},{"key":"762_CR58","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000021661","volume":"99","author":"MR Jordan","year":"2020","unstructured":"Jordan MR, Hamunime N, Bikinesi L, et al. High levels of HIV drug resistance among adults failing second-line antiretroviral therapy in Namibia. Medicine. 2020;99:E21661. https:\/\/doi.org\/10.1097\/MD.0000000000021661.","journal-title":"Medicine"},{"key":"762_CR59","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.15406\/jhvrv.2016.03.00086","volume":"3","author":"F Clavel","year":"2004","unstructured":"Clavel F, Hance A. HIV drug resistance. N Engl J Med. 2004;3:1023\u201335. https:\/\/doi.org\/10.15406\/jhvrv.2016.03.00086.","journal-title":"N Engl J Med"},{"key":"762_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pcbi.1008873","volume":"17","author":"L Blassel","year":"2021","unstructured":"Blassel L, Tostevin A, Villabona-Arenas CJ, et al. Using machine learning and big data to explore the drug resistance landscape in HIV. PLoS Comput Biol. 2021;17:1\u201321. https:\/\/doi.org\/10.1371\/journal.pcbi.1008873.","journal-title":"PLoS Comput Biol"},{"key":"762_CR61","unstructured":"N. M. Resistance to non-nucleoside reverse transcriptase inhibitors. In: A.M. G, editor Antiretroviral resistance in clinical practice. Mediscript, London;\u00a02006."},{"key":"762_CR62","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac443","author":"GM Hunt","year":"2023","unstructured":"Hunt GM, Yousif M, Levin L, et al. Resistance is common in paediatric patients failing ART in South Africa. J Antimicrob Chemother. 2023. https:\/\/doi.org\/10.1093\/jac\/dkac443.","journal-title":"J Antimicrob Chemother"},{"key":"762_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/v15102083","volume":"15","author":"L Abuogi","year":"2023","unstructured":"Abuogi L, Oyaro P, Wakjira G, et al. HIV drug resistance patterns and characteristics associated with clinically significant drug resistance among children with virologic failure on antiretroviral treatment in kenya: findings from the Opt4Kids randomized controlled trial. Viruses. 2023;15:1\u201315. https:\/\/doi.org\/10.3390\/v15102083.","journal-title":"Viruses"},{"key":"762_CR64","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1093\/jac\/dkad010","volume":"78","author":"D Kamori","year":"2023","unstructured":"Kamori D, Barabona G, Rugemalila J, et al. Emerging integrase strand transfer inhibitor drug resistance mutations among children and adults on ART in tanzania: findings from a national representative HIV drug resistance survey. J Antimicrob Chemother. 2023;78:779\u201387. https:\/\/doi.org\/10.1093\/jac\/dkad010.","journal-title":"J Antimicrob Chemother"},{"key":"762_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0305129","volume":"19","author":"GA Namayanja","year":"2024","unstructured":"Namayanja GA, de Fatima Da Silva J, Elur B, et al. High viral suppression rates among PLHIV on dolutegravir who had an initial episode of viral non-suppression in Uganda September 2020\u2013July 2021. PLoS ONE. 2024;19:1\u201313. https:\/\/doi.org\/10.1371\/journal.pone.0305129.","journal-title":"PLoS ONE"},{"key":"762_CR66","unstructured":"Bello G. Emerging dolutegravir resistance among children being investigated for treatment failure in Malawi. In: Conference on retroviruses and opportunistic infections. Denver; 2024."},{"key":"762_CR67","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000876","author":"A Bamford","year":"2024","unstructured":"Bamford A, Hamzah L, Turkova A. Paediatric antiretroviral therapy challenges with emerging integrase resistance. Curr Opin HIV AIDS. 2024. https:\/\/doi.org\/10.1097\/COH.0000000000000876.","journal-title":"Curr Opin HIV AIDS"},{"key":"762_CR68","doi-asserted-by":"publisher","DOI":"10.1093\/OFID\/OFAA202","author":"M Cevik","year":"2020","unstructured":"Cevik M, Orkin C, Sax PE. Emergent resistance to dolutegravir among instinaive patients on first-line or second-line antiretroviral therapy: a review of published cases. Open Forum Infect Dis. 2020. https:\/\/doi.org\/10.1093\/OFID\/OFAA202.","journal-title":"Open Forum Infect Dis"},{"key":"762_CR69","doi-asserted-by":"publisher","first-page":"S127","DOI":"10.1097\/QAD.0000000000003082","volume":"35","author":"SM McCluskey","year":"2021","unstructured":"McCluskey SM, Pepperrell T, Hill A, et al. Adherence, resistance, and viral suppression on dolutegravir in sub-Saharan africa: implications for the TLD era. Aids. 2021;35:S127\u201335. https:\/\/doi.org\/10.1097\/QAD.0000000000003082.","journal-title":"Aids"},{"key":"762_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40795-023-00774-1","volume":"9","author":"M Bwakura-Dangarembizi","year":"2023","unstructured":"Bwakura-Dangarembizi M, Ziemba L, Tierney C, et al. Micronutrients and nutritional status among children living with HIV with and without severe acute malnutrition: IMPAACT P1092. BMC Nutr. 2023;9:1\u20139. https:\/\/doi.org\/10.1186\/s40795-023-00774-1.","journal-title":"BMC Nutr"},{"key":"762_CR71","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1093\/advances\/nmaa163","volume":"12","author":"OK Fabusoro","year":"2021","unstructured":"Fabusoro OK, Mejia LA. Nutrition in HIV-Infected Infants and Children: Current Knowledge, Existing Challenges, and New Dietary Management Opportunities. Adv Nutr. 2021;12(4):1424\u20131437. https:\/\/doi.org\/10.1093\/advances\/nmaa163.","journal-title":"Adv Nutr"},{"key":"762_CR72","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/351043","author":"HC Anyabolu","year":"2014","unstructured":"Anyabolu HC, Adejuyigbe EA, Adeodu OO. Serum micronutrient status of Haart-na\u00efve, HIV infected children in South Western Nigeria: a case controlled study. AIDS Res Treat. 2014. https:\/\/doi.org\/10.1155\/2014\/351043.","journal-title":"AIDS Res Treat"},{"key":"762_CR73","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1097\/01.aids.0000171398.77500.a9","volume":"19","author":"AM Tang","year":"2005","unstructured":"Tang AM, Lanzillotti J, Hendricks K, et al. Micronutrients: current issues for HIV care providers. AIDS. 2005;19:847\u201361. https:\/\/doi.org\/10.1097\/01.aids.0000171398.77500.a9.","journal-title":"AIDS"},{"key":"762_CR74","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1177\/154510970200100205","volume":"1","author":"N Singhal","year":"2002","unstructured":"Singhal N, Austin J. A clinical review of micronutrients in HIV infection. J Int Assoc Physicians AIDS Care (Chic). Springer. 2002;1(2):63\u201375. https:\/\/doi.org\/10.1177\/154510970200100205.","journal-title":"J Int AIDS Soc"},{"key":"762_CR75","doi-asserted-by":"publisher","unstructured":"Irlam JH, Siegfried N, Visser ME, et al. Micronutrient supplementation for children with HIV infection. Cochrane Database Syst Rev. 2013;10. https:\/\/doi.org\/10.1002\/14651858.CD010666.","DOI":"10.1002\/14651858.CD010666"},{"key":"762_CR76","doi-asserted-by":"publisher","first-page":"C61","DOI":"10.1016\/j.vaccine.2012.02.040","volume":"30","author":"MJ Mphahlele","year":"2012","unstructured":"Mphahlele MJ, Mda S. Immunising the HIV-infected child: A view from sub-Saharan Africa. Vaccine. 2012;30:C61\u20135. https:\/\/doi.org\/10.1016\/j.vaccine.2012.02.040.","journal-title":"Vaccine"},{"key":"762_CR77","unstructured":"WHO. Table 3: recommendations for interrupted or delayed. Routine immunization - Summary of WHO position papers; 2024."},{"key":"762_CR78","doi-asserted-by":"publisher","unstructured":"MacNeil JR, Rubin LG, Patton M, Ortega-Sanchez IR, Martin SW. Recommendations for Use of Meningococcal Conjugate Vaccines in HIV-Infected Persons - Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2016;65(43):1189\u20131194. https:\/\/doi.org\/10.15585\/mmwr.mm6543a3.","DOI":"10.15585\/mmwr.mm6543a3"},{"issue":"1","key":"762_CR79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jinf.2017.04.007","volume":"75","author":"R Borrow","year":"2017","unstructured":"Borrow R, Caugant DA, Ceyhan M, et al. Meningococcal disease in the Middle East and Africa: findings and updates from the global meningococcal initiative. J Infect. 2017;75(1):1\u201311. https:\/\/doi.org\/10.1016\/j.jinf.2017.04.007.","journal-title":"J Infect"},{"key":"762_CR80","doi-asserted-by":"publisher","unstructured":"Lawler M, Naby F. Opportunistic Infections. In: Bobat, R. (eds) HIV Infection in Children and Adolescents. Springer, Cham. 2020. https:\/\/doi.org\/10.1007\/978-3-030-35433-6_14.","DOI":"10.1007\/978-3-030-35433-6_14"},{"key":"762_CR81","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1093\/cid\/ciae051","volume":"79","author":"C Bielick","year":"2024","unstructured":"Bielick C, Strumpf A, Ghosal S, et al. National hospitalization rates and in-hospital mortality rates of HIV\u2013related opportunistic infections in the United States, 2011\u20132018. Clin Infect Dis. 2024;79:487\u201397. https:\/\/doi.org\/10.1093\/cid\/ciae051.","journal-title":"Clin Infect Dis"},{"key":"762_CR82","unstructured":"WHO. Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy. Geneva;\u00a02017."},{"key":"762_CR83","volume-title":"Package of care for children and adolescents with advanced HIV disease stop AIDS. Technical brief","author":"WHO","year":"2020","unstructured":"WHO. Package of care for children and adolescents with advanced HIV disease stop AIDS. Technical brief. Geneva: World Health Organization; 2020."},{"key":"762_CR84","doi-asserted-by":"publisher","first-page":"809","DOI":"10.4314\/ejhs.v32i4.18","volume":"32","author":"RSR Sutini","year":"2022","unstructured":"Sutini RSR, Saefurrohim MZ, et al. Prevalence and determinants of opportunistic infections in HIV patients: a cross-sectional study in the city of Semarang. Ethiop J Health Sci. 2022;32:809\u201316. https:\/\/doi.org\/10.4314\/ejhs.v32i4.18.","journal-title":"Ethiop J Health Sci"},{"key":"762_CR85","doi-asserted-by":"crossref","unstructured":"Rubaihayo J, Mbona Tumwesigye N, Birungi J. Temporal and spatial distribution of opportunistic infections associated with the Human Immunodeficiency Virus (HIV) in Uganda; 2023.","DOI":"10.5772\/intechopen.105344"},{"key":"762_CR86","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0282936","volume":"18","author":"G Lubega","year":"2023","unstructured":"Lubega G, Abaasa A, Ochola W, et al. The bacterial profile and antibiotic susceptibility pattern in respiratory tract samples from art-experienced HIV-positive adults in Uganda. PLoS ONE. 2023;18:e0282936. https:\/\/doi.org\/10.1371\/journal.pone.0282936.","journal-title":"PLoS ONE"},{"key":"762_CR87","doi-asserted-by":"publisher","unstructured":"Boyd AT, Oboho I, Paulin H, et al. Addressing advanced HIV disease and mortality in global HIV programming. AIDS Res Ther 2020;17(1):40. https:\/\/doi.org\/10.1186\/s12981-020-00296-x","DOI":"10.1186\/s12981-020-00296-x"},{"key":"762_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.dialog.2023.100120","author":"CE Bekolo","year":"2023","unstructured":"Bekolo CE, Ndeso SA, Gougue CP, et al. The effect of the universal test and treat policy uptake on CD4 count testing and incidence of opportunistic infections among people living with HIV infection in Cameroon: a retrospective analysis of routine data. Dialogues in Health. 2023. https:\/\/doi.org\/10.1016\/j.dialog.2023.100120.","journal-title":"Dialogues in Health"},{"key":"762_CR89","doi-asserted-by":"crossref","unstructured":"Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH. Red book: 2021 report of the committee on infectious diseases. 32nd ed. American Academy of Pediatrics; 2021.","DOI":"10.1542\/9781610025225"},{"key":"762_CR90","unstructured":"Kliegman RM, Geme JW, Blum NJ, et al. Nelson textbook of pediatrics. 21st ed. Elsevier; 2020."},{"key":"762_CR91","unstructured":"Guidelines for the prevention and treatment of opportunistic infections in children with and exposed to HIV; 2025. In: NIH. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-pediatric-opportunistic-infections\/whats-new. Accessed 7 Oct 2025."},{"key":"762_CR92","unstructured":"World Health Organization (WHO). Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents, and children living with HIV; 2022."},{"key":"762_CR93","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1093\/cid\/ciac658","volume":"76","author":"I Mastrorosa","year":"2023","unstructured":"Mastrorosa I, Pinnetti C, Brita AC, et al. Declining prevalence of human immunodeficiency virus (HIV)-Associated neurocognitive disorders in recent years and associated factors in a large Cohor of antiretroviral Therapy-Treated individuals with HIV. Clin Infect Dis. 2023;76:629\u201337. https:\/\/doi.org\/10.1093\/cid\/ciac658.","journal-title":"Clin Infect Dis"},{"key":"762_CR94","doi-asserted-by":"publisher","unstructured":"Musindo O, Krabbendam L, Mutahi J, et al. Neurocognitive deficits and socioeconomic risk factors among children and adolescents living with HIV in sub-Saharan Africa: a systematic review. Child Adolesc Psychiatry Ment Health. 2022;16(1):31. https:\/\/doi.org\/10.1186\/s13034-022-00465-y.","DOI":"10.1186\/s13034-022-00465-y"},{"key":"762_CR95","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.3390\/v13122543","volume":"13","author":"M Williams","year":"2021","unstructured":"Williams M, Van Rensburg AJ, Loots DT, et al. Immune dysregulation is associated with neurodevelopment and neurocognitive performance in HIV pediatric Populations-A scoping review. Viruses. 2021;13:2543. https:\/\/doi.org\/10.3390\/v13122543.","journal-title":"Viruses"},{"key":"762_CR96","doi-asserted-by":"publisher","unstructured":"vanWyhe KS, Laughton B, Cotton MF, et al. Cognitive outcomes at ages seven and nine years in South African children from the children with HIV early antiretroviral (CHER) trial: a longitudinal investigation. 2021. https:\/\/doi.org\/10.1002\/jia2.25734\/full.","DOI":"10.1002\/jia2.25734\/full"},{"key":"762_CR97","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1097\/QAI.0000000000003165","volume":"93","author":"S Benki-Nugent","year":"2023","unstructured":"Benki-Nugent S, Tamasha N, Mueni A, et al. Early antiretroviral therapy reduces severity but does not eliminate neurodevelopmental compromise in children with HIV. J Acquir Immune Defic Syndr. 2023;93:7\u201314. https:\/\/doi.org\/10.1097\/QAI.0000000000003165.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"762_CR98","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0285761","volume":"18","author":"AA Nyundo","year":"2023","unstructured":"Nyundo AA. Correlates of the HIV-associated neurocognitive disorders among adults living with HIV in Dodoma region, central Tanzania: a cross-sectional study. PLoS ONE. 2023;18:e0285761. https:\/\/doi.org\/10.1371\/journal.pone.0285761.","journal-title":"PLoS ONE"},{"key":"762_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(23)00051-6","author":"JB Nachega","year":"2023","unstructured":"Nachega JB, Scarsi KK, Gandhi M, et al. Long-acting antiretrovirals and HIV treatment adherence. Lancet HIV. 2023. https:\/\/doi.org\/10.1016\/S2352-3018(23)00051-6.","journal-title":"Lancet HIV"},{"key":"762_CR100","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1097\/QAI.0000000000001896","volume":"80","author":"ED Weld","year":"2019","unstructured":"Weld ED, Sohel RANAM, Dallas RH, et al. Interest of youth living with HIV in Long-Acting antiretrovirals HHS public access. J Acquir Immune Defic Syndr. 2019;80:190\u20137. https:\/\/doi.org\/10.1097\/QAI.0000000000001896.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"762_CR101","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1007\/s10461-022-03949-2","volume":"27","author":"E Toska","year":"2023","unstructured":"Toska E, Zhou S, Chen-Charles J, et al. Factors associated with preferences for long-acting injectable antiretroviral therapy among adolescents and young people living with HIV in South Africa. AIDS Behav. 2023;27:2163\u201375. https:\/\/doi.org\/10.1007\/s10461-022-03949-2.","journal-title":"AIDS Behav"},{"key":"762_CR102","unstructured":"Young people\u2019s Lusaka Declaration. In: 9th Int. Work. Adolesc. SRHR, HIV. 2025. https:\/\/virology.eventsair.com\/international-workshop-on-hiv-adolescence-2023\/youth-declaration\/Site\/Register."},{"key":"762_CR103","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1097\/COH.0000000000000880","volume":"19","author":"N Rakhmanina","year":"2024","unstructured":"Rakhmanina N, Foster C, Agwu A. Adolescents and young adults with HIV and unsuppressed viral load: where do we go from here? Curr Opin HIV AIDS. 2024;19:1746\u2013X630. https:\/\/doi.org\/10.1097\/COH.0000000000000880.","journal-title":"Curr Opin HIV AIDS"},{"issue":"6","key":"762_CR104","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/S40272-024-00656-4","volume":"26","author":"AEM Kamphuis","year":"2024","unstructured":"Kamphuis AEM, Bamford A, Tagarro A, et al. Optimising paediatric HIV treatment: recent developments and future directions. Pediatr Drugs. 2024;26(6):631\u201348. https:\/\/doi.org\/10.1007\/S40272-024-00656-4.","journal-title":"Pediatr Drugs"},{"key":"762_CR105","unstructured":"WHO. Pediatric drug optimization standard procedure. Geneva; 2021."},{"key":"762_CR106","unstructured":"WHO Global Accelerator for Paediatric Formulations Network. (GAP-f). https:\/\/www.who.int\/initiatives\/gap-f. Accessed 7 Sep 2025."},{"issue":"10","key":"762_CR107","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41579-023-00914-1","volume":"21","author":"RJ Landovitz","year":"2023","unstructured":"Landovitz RJ, Scott H, Deeks SG. Prevention, treatment and cure of HIV infection. Nat Rev Microbiol. 2023;21(10):657\u201370. https:\/\/doi.org\/10.1038\/s41579-023-00914-1.","journal-title":"Nat Rev Microbiol"},{"key":"762_CR108","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/QAD.0000000000002043","volume":"33","author":"VA Vieira","year":"2019","unstructured":"Vieira VA, Zuidewind P, Muenchhoff M, et al. Strong sex bias in elite control of paediatric HIV infection. AIDS. 2019;33:67\u201375. https:\/\/doi.org\/10.1097\/QAD.0000000000002043.","journal-title":"AIDS"},{"key":"762_CR109","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aag1048.NON-PROGRESSING","author":"M Muenchhoff","year":"2016","unstructured":"Muenchhoff M, Adland E, Karimanzira O, et al. Non-Progressing HIV-Infected children share fundamental immunological features of Non-Pathogenic SIV infection. Sci Transl Med. 2016. https:\/\/doi.org\/10.1126\/scitranslmed.aag1048.NON-PROGRESSING. 8:.","journal-title":"Sci Transl Med"},{"key":"762_CR110","unstructured":"New global alliance launched to end AIDS in children by 2030; 2022. https:\/\/www.who.int\/news\/item\/02-08-2022-new-global-alliance-launched-to-end-aids-in-children-by-2030. Accessed 19 Aug 2025."}],"container-title":["Current HIV\/AIDS Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-025-00762-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11904-025-00762-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-025-00762-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T14:03:41Z","timestamp":1769609021000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11904-025-00762-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":110,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["762"],"URL":"https:\/\/doi.org\/10.1007\/s11904-025-00762-z","relation":{},"ISSN":["1548-3568","1548-3576"],"issn-type":[{"value":"1548-3568","type":"print"},{"value":"1548-3576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"17 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"52"}}